April 23, 2024

Magnificent Seven’ Prepares to Announce Earnings Amid Market Recovery

Tesla Ends Week-Long Slide Before Earnings; Bond Market Stabilizes After $69 Billion Treasury Sale As tech giants brace to release their earnings, the broader stock market is witnessing a rally, led by the much-watched ‘Magnificent Seven.’ Wall Street views these forthcoming earnings as a critical test of the ongoing equities bull run. Each member of… [Read More]
April 23, 2024

Spotify jumps starts the spring with a gain

Spotify Technologies (NYSE: SPOT), a renowned audio-streaming platform, saw a notable rise in its share prices on Tuesday post their Q1 2024 financial results announcement. At 9:40 a.m. ET, the company’s stock had soared by 13% and was reaching new 52-week highs. Achieving Profits through Steady Growth Spotify closed Q1 with 615 million monthly active… [Read More]
April 22, 2024

FDA Places Hold on Neumora Schizophrenia Study

The FDA has placed a clinical hold on Neumora Therapeutics’ (Nasdaq: NMRA) Phase 1 trial of NMRA-266 after the compound resulted in convulsions in rabbits in the company’s preclinical studies. The company’s stock tumbled 17.5% to close at $11.19 after the announcement last week. The stock closed down an additional 3.51% on Friday and has… [Read More]
April 22, 2024

M&A Moves: Matterport (MTTR) To Be Acquired By CoStar Group, Stock Up 176% On Report

Today the technology company specializing in creating immersive 3D experiences of physical spaces Matterport, Inc. (MTTR) announced today that it has entered into a definitive agreement with CoStar Group, Inc. (CSGP) who will acquire all of Matterport’s outstanding shares in a cash and stock transaction valued at $5.50 per share. This represents an equity value of… [Read More]
April 22, 2024

YS Biopharma to Initiate Hepatitis B Vaccine Trial in Philippines

Global biopharmaceutical company, YS Biopharma (Nasdaq: YS) has been granted clinical trial approval in the Philippines for its YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B virus (HBV) infection. YS expects to initiate a Phase 1 clinical trial in the Philippines in June 2024. Chronic HBV infection is a significant unaddressed public health threat, with 1.2… [Read More]
April 22, 2024

Nxera Pharma and Neurocrine Biosciences Complete Preclinical Toxicity Program in Schizophrenia Drug Hopeful

Nxera Pharma (OTC: SOLTF) and Neurocrine Biosciences (Nasdaq: NBIX) have successfully completed a long-term preclinical toxicity program for NBI-1117568, which is in Phase 2 clinical trials for the treatment of schizophrenia and other neuropsychiatric disorders. The studies have shown that NBI-1117568 meets FDA requirements to allow for safe, long term dosing in future clinical trials…. [Read More]